Proof of principle for epitope-focused vaccine design
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
Vaccines prevent infectious disease largely by inducing protective neutralizing antibodies against vulnerable epitopes. Several major pathogens have resisted traditional vaccine development, although vulnerable epitopes targeted by neutralizing antibodies have been identified for several such cases. Hence, new vaccine design methods to induce epitope-specific neutralizing antibodies are needed. Here we show, with a neutralization epitope from respiratory syncytial virus, that computational protein design can generate small, thermally and conformationally stable protein scaffolds that accurately mimic the viral epitope structure and induce potent neutralizing antibodies. These scaffolds represent promising leads for the research and development of a human respiratory syncytial virus vaccine needed to protect infants, young children and the elderly. More generally, the results provide proof of principle for epitope-focused and scaffold-based vaccine design, and encourage the evaluation and further development of these strategies for a variety of other vaccine targets, including antigenically highly variable pathogens such as human immunodeficiency virus and influenza.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
The global distribution and burden of dengue
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., et al. (2013) · Nature · doi:10.1038/nature12060 · Cited by 10,037
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
NMR View: A computer program for the visualization and analysis of NMR data
Johnson, B. A., & Blevins, R. A. (1994) · Journal of Biomolecular NMR · doi:10.1007/bf00404272 · Cited by 3,090
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Leaver-Fay (2011) · doi:10.1016/b978-0-12-381270-4.00019-6 · Cited by 1,904
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
Protein Structure Prediction Using Rosetta
Rohl, C. A., Strauss, C. E. M., Misura, K. M. S., & Baker, D. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)83004-0 · Cited by 1,725
Self-citationDesign of a Novel Globular Protein Fold with Atomic-Level Accuracy
Kuhlman, B., Dantas, G., Ireton, G. C., Varani, G., Stoddard, B. L., & Baker, D. (2003) · Science · doi:10.1126/science.1089427 · Cited by 1,670
Self-citation
Research works printed but not linked: 1
- Plotkin SA Orenstein WA Offit PA Vaccines 6 Elsevier 2012
Cited by
The Rosetta All-Atom Energy Function for Macromolecular Modeling and Design
Alford, R. F., Leaver-Fay, A., Jeliazkov, J. R., O’Meara, M. J., DiMaio, F. P., Park, H., Shapovalov, M. V., Renfrew, P. D., Mulligan, V. K., Kappel, K., et al. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.7b00125 · Cited by 1,532
Self-citationThe coming of age of de novo protein design
Huang, P.-S., Boyken, S. E., & Baker, D. (2016) · Nature · doi:10.1038/nature19946 · Cited by 1,478
Self-citationMacromolecular modeling and design in Rosetta: recent methods and frameworks
Leman, J. K., Weitzner, B. D., Lewis, S. M., Adolf-Bryfogle, J., Alam, N., Alford, R. F., Aprahamian, M., Baker, D., Barlow, K. A., Barth, P., et al. (2020) · Nature Methods · doi:10.1038/s41592-020-0848-2 · Cited by 888
Self-citationDeciphering interaction fingerprints from protein molecular surfaces using geometric deep learning
Gainza, P., Sverrisson, F., Monti, F., Rodolà, E., Boscaini, D., Bronstein, M. M., & Correia, B. E. (2020) · Nature Methods · doi:10.1038/s41592-019-0666-6 · Cited by 834
Self-citationAdvances in protein structure prediction and design
Kuhlman, B., & Bradley, P. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0163-x · Cited by 806
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen
Impagliazzo, A., Milder, F., Kuipers, H., Wagner, M. V., Zhu, X., Hoffman, R. M. B., van Meersbergen, R., Huizingh, J., Wanningen, P., Verspuij, J., et al. (2015) · Science · doi:10.1126/science.aac7263 · Cited by 600
Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer
Walls, A. C., Tortorici, M. A., Bosch, B.-J., Frenz, B., Rottier, P. J. M., DiMaio, F., Rey, F. A., & Veesler, D. (2016) · Nature · doi:10.1038/nature16988 · Cited by 538
Broad neutralization of SARS-related viruses by human monoclonal antibodies
Wec, A. Z., Wrapp, D., Herbert, A. S., Maurer, D. P., Haslwanter, D., Sakharkar, M., Jangra, R. K., Dieterle, M. E., Lilov, A., Huang, D., et al. (2020) · Science · doi:10.1126/science.abc7424 · Cited by 539
Self-citationDe novo design of potent and selective mimics of IL-2 and IL-15
Silva, D.-A., Yu, S., Ulge, U. Y., Spangler, J. B., Jude, K. M., Labão-Almeida, C., Ali, L. R., Quijano-Rubio, A., Ruterbusch, M., Leung, I., et al. (2019) · Nature · doi:10.1038/s41586-018-0830-7 · Cited by 531
Self-citationScaffolding protein functional sites using deep learning
Wang, J., Lisanza, S., Juergens, D., Tischer, D., Watson, J. L., Castro, K. M., Ragotte, R., Saragovi, A., Milles, L. F., Baek, M., et al. (2022) · Science · doi:10.1126/science.abn2100 · Cited by 487
“…acid identities which produce the desired activity--for enzymes this can be done using quantum chemistry calculations (1–3) and for protein binders by fragment docking calculations (4, 5); alternatively, functional sites can be extracted from a native protein having the desired activity (6, 7).”
BackgroundMethodSelf-citationReverse vaccinology 2.0: Human immunology instructs vaccine antigen design
Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O., & De Gregorio, E. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151960 · Cited by 435
“Subsequently, Correia et al. (2014) reported a proof-of-principle study, wherein they developed a new structure-based approach for the computational design and optimization of improved biophysically robust scaffold proteins displaying the desired RSV peptide epitope in a conformationally faithful…”
BackgroundTam, H. H., Melo, M. B., Kang, M., Pelet, J. M., Ruda, V. M., Foley, M. H., Hu, J. K., Kumari, S., Crampton, J., Baldeon, A. D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606050113 · Cited by 425
Duan, L., Zheng, Q., Zhang, H., Niu, Y., Lou, Y., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576622 · Cited by 408
“The epitope-focused vaccine design has proven to be successful in generating neutralizing antibodies against RSV fusion glycoprotein (111).”
BackgroundTrimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G
Stewart-Jones, G. B. E., Soto, C., Lemmin, T., Chuang, G.-Y., Druz, A., Kong, R., Thomas, P. V., Wagh, K., Zhou, T., Behrens, A.-J., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.010 · Cited by 404
Broad betacoronavirus neutralization by a stem helix–specific human antibody
Pinto, D., Sauer, M. M., Czudnochowski, N., Low, J. S., Tortorici, M. A., Housley, M. P., Noack, J., Walls, A. C., Bowen, J. E., Guarino, B., et al. (2021) · Science · doi:10.1126/science.abj3321 · Cited by 388
Structural Basis of Zika Virus-Specific Antibody Protection
Zhao, H., Fernandez, E., Dowd, K. A., Speer, S. D., Platt, D. J., Gorman, M. J., Govero, J., Nelson, C. A., Pierson, T. C., Diamond, M. S., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.020 · Cited by 375
“Masking of epitopes that fail to elicit neutralizing antibodies could be combined with epitope-focused vaccine design approaches (Correia et al., 2014) to generate DIII variants that induce more protective responses.”
Self-assembling protein nanoparticles in the design of vaccines
López-Sagaseta, J., Malito, E., Rappuoli, R., & Bottomley, M. J. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.11.001 · Cited by 353
“The antigen alone was moderately immunogenic, but showed a much higher ability to induce protective RSV-neutralizingantibodies in several animal models including rhesus macaques when it was presented in multiple copies on the HBcAg scaffold [68].”
Progress in biopharmaceutical development
Kesik‐Brodacka, M. (2018) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1617 · Cited by 353
Vaccines, new opportunities for a new society
Rappuoli, R., Pizza, M., Del Giudice, G., & De Gregorio, E. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402981111 · Cited by 335
Shingai, M., Donau, O. K., Plishka, R. J., Buckler-White, A., Mascola, J. R., Nabel, G. J., Nason, M. C., Montefiori, D., Moldt, B., Poignard, P., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20132494 · Cited by 321
HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure
Kwong, P. D., & Mascola, J. R. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.029 · Cited by 304
High frequency of shared clonotypes in human B cell receptor repertoires
Soto, C., Bombardi, R. G., Branchizio, A., Kose, N., Matta, P., Sevy, A. M., Sinkovits, R. S., Gilchuk, P., Finn, J. A., & Crowe, J. E. (2019) · Nature · doi:10.1038/s41586-019-0934-8 · Cited by 294
Self-citationZhu, J., Avakyan, N., Kakkis, A., Hoffnagle, A. M., Han, K., Li, Y., Zhang, Z., Choi, T. S., Na, Y., Yu, C.-J., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00308 · Cited by 285
Self-citationAntibodies to combat viral infections: development strategies and progress
Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S., & Perez, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 279
Self-citationProtein-based antigen presentation platforms for nanoparticle vaccines
Nguyen, B., & Tolia, N. H. (2021) · npj Vaccines · doi:10.1038/s41541-021-00330-7 · Cited by 271
Modeling and docking of antibody structures with Rosetta
Weitzner, B. D., Jeliazkov, J. R., Lyskov, S., Marze, N., Kuroda, D., Frick, R., Adolf-Bryfogle, J., Biswas, N., Dunbrack, R. L., & Gray, J. J. (2017) · Nature Protocols · doi:10.1038/nprot.2016.180 · Cited by 264
“Atomic detail is required to consider specific antibody–antigen interactions, for example, in order to develop therapeutic antibodies or vaccines that are mimetics of extremely infectious antigens 3 .”
BackgroundDe novo design of a four-fold symmetric TIM-barrel protein with atomic-level accuracy
Huang, P.-S., Feldmeier, K., Parmeggiani, F., Fernandez Velasco, D. A., Höcker, B., & Baker, D. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1966 · Cited by 251
“There has been progress in de novo design of protein structures 1-8 , but designing all-β and α / β barrels has proven very challenging.”
Self-citationStructure-Based Vaccine Antigen Design
Graham, B. S., Gilman, M. S. A., & McLellan, J. S. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-121217-094234 · Cited by 234
“To improve upon these first-generation immunogens, a computational approach called Fold From Loops was developed and used to design new epitope scaffolds that contained all of antigenic site II and presented it in a conformation that was nearly identical to that observed in crystal structures of RSV F (69).”
MethodSelf-citationDeep Learning in Protein Structural Modeling and Design
Gao, W., Mahajan, S. P., Sulam, J., & Gray, J. J. (2020) · Patterns · doi:10.1016/j.patter.2020.100142 · Cited by 227
Engineering cytokine therapeutics
Deckers, J., Anbergen, T., Hokke, A. M., de Dreu, A., Schrijver, D. P., de Bruin, K., Toner, Y. C., Beldman, T. J., Spangler, J. B., de Greef, T. F. A., et al. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00030-y · Cited by 214
Murin, C. D., Wilson, I. A., & Ward, A. B. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0392-y · Cited by 213
De novo protein design enables the precise induction of RSV-neutralizing antibodies
Sesterhenn, F., Yang, C., Bonet, J., Cramer, J. T., Wen, X., Wang, Y., Chiang, C.-I., Abriata, L. A., Kucharska, I., Castoro, G., et al. (2020) · Science · doi:10.1126/science.aay5051 · Cited by 191
“stabilize these structures, we used Rosetta FunFolDes as described previously (9, 34).”
BackgroundMethodResultInfluentialSelf-citationCOVID-19 and SARS-CoV-2. Modeling the present, looking at the future
Estrada, E. (2020) · Physics Reports · doi:10.1016/j.physrep.2020.07.005 · Cited by 199
Protein–protein interaction prediction with deep learning: A comprehensive review
Soleymani, F., Paquet, E., Viktor, H., Michalowski, W., & Spinello, D. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.08.070 · Cited by 191
“Some of the successful examples include novel folds in protein design [74,75], enzymes [76,77], antibodies [78–80], vaccines [78,81], ligand-binding proteins [82,83], protein assemblies [84– 88], and membrane proteins [89–91].”
BackgroundStructural basis for broad coronavirus neutralization
Sauer, M. M., Tortorici, M. A., Park, Y.-J., Walls, A. C., Homad, L., Acton, O. J., Bowen, J. E., Wang, C., Xiong, X., de van der Schueren, W., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00596-4 · Cited by 187
Opportunities and challenges in design and optimization of protein function
Listov, D., Goverde, C. A., Correia, B. E., & Fleishman, S. J. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00718-y · Cited by 180
“One promising application in the field of de novo design is the creation of vaccine immunogens 151,162 .”
Self-citationDesign of coiled-coil protein-origami cages that self-assemble in vitro and in vivo
Ljubetič, A., Lapenta, F., Gradišar, H., Drobnak, I., Aupič, J., Strmšek, Ž., Lainšček, D., Hafner-Bratkovič, I., Majerle, A., Krivec, N., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3994 · Cited by 178
Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection
Sommerstein, R., Flatz, L., Remy, M. M., Malinge, P., Magistrelli, G., Fischer, N., Sahin, M., Bergthaler, A., Igonet, S., ter Meulen, J., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005276 · Cited by 174
Protein sequence design with a learned potential
Anand, N., Eguchi, R., Mathews, I. I., Perez, C. P., Derry, A., Altman, R. B., & Huang, P.-S. (2022) · Nature Communications · doi:10.1038/s41467-022-28313-9 · Cited by 171
“omputational protein design has emerged as a powerful tool for rational protein design, enabling signi fi cant achievements in the engineering of therapeutics 1 – 3 , 4 – 6 , enzymes 7,8 , and more 9 – 11 .”
BackgroundMethodInfluentialSelf-assembly of genetically encoded DNA-protein hybrid nanoscale shapes
Praetorius, F., & Dietz, H. (2017) · Science · doi:10.1126/science.aam5488 · Cited by 171
Eliciting B cell immunity against infectious diseases using nanovaccines
Singh, A. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00790-3 · Cited by 169
Robinson, J. E., Hastie, K. M., Cross, R. W., Yenni, R. E., Elliott, D. H., Rouelle, J. A., Kannadka, C. B., Smira, A. A., Garry, C. E., Bradley, B. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11544 · Cited by 169
Computational Protein Design with Deep Learning Neural Networks
Wang, J., Cao, H., Zhang, J. Z. H., & Qi, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-24760-x · Cited by 166
Greiff, V., Menzel, U., Miho, E., Weber, C., Riedel, R., Cook, S., Valai, A., Lopes, T., Radbruch, A., Winkler, T. H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.054 · Cited by 164
“…2016; Galson et al., 2015b; Glanville et al., 2011) and clonal repertoire, elicitation of neutralizing antibodies may be accomplished in a large proportion of the population by targeting highly represented germlines and public clones using computationally designed immunogens (Correia et al., 2014).”
BackgroundDesigning and building the next generation of improved vaccine adjuvants
Brito, L. A., & O'Hagan, D. T. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.027 · Cited by 158
Bajic, G., Maron, M. J., Adachi, Y., Onodera, T., McCarthy, K. R., McGee, C. E., Sempowski, G. D., Takahashi, Y., Kelsoe, G. H., Kuraoka, M., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.04.003 · Cited by 167
“Strategies to alter patternsof immunodominanceoften focuson rational immunogen design approaches aimed at eliciting broadly neutralizing antibodies (bnAbs) (Correia et al., 2014; Haynes et al., 2012; Jardine et al., 2015;Mascola andHaynes, 2013).”
Self-citationA high‐throughput shotgun mutagenesis approach to mapping B‐cell antibody epitopes
Davidson, E., & Doranz, B. J. (2014) · Immunology · doi:10.1111/imm.12323 · Cited by 160
Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies
Alanine, D. G. W., Quinkert, D., Kumarasingha, R., Mehmood, S., Donnellan, F. R., Minkah, N. K., Dadonaite, B., Diouf, A., Galaway, F., Silk, S. E., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.025 · Cited by 153
Novel antigens for RSV vaccines
Graham, B. S., Modjarrad, K., & McLellan, J. S. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.04.005 · Cited by 154
“Recently, Schief and colleagues computationally designed novel proteins that correctly displayed antigenic site II and bound to motavizumab with picomolar affinity (38).”
BackgroundSelf-citationNeutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2
Sun, X., Yi, C., Zhu, Y., Ding, L., Xia, S., Chen, X., Liu, M., Gu, C., Lü, X., Fu, Y., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01155-3 · Cited by 155
Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein
McLellan, J. S. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.002 · Cited by 147
Jorge, S., & Dellagostin, O. A. (2017) · Biotechnology Research and Innovation · doi:10.1016/j.biori.2017.10.001 · Cited by 138
Self-replicating alphavirus RNA vaccines
Ljungberg, K., & Liljeström, P. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.965690 · Cited by 137
“These include reverse vaccinology [166], computational [167], structural [168,169], systems [170,171] and synthetic biology [79].”
BackgroundAntibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization
Kong, R., Duan, H., Sheng, Z., Xu, K. Y., Acharya, P., Chen, X., Cheng, C.-C., Dingens, A. S., Gorman, J., Sastry, M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.030 · Cited by 136
Burton, D. R. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a030262 · Cited by 133
“A second approach is described by Schief and coworkers in which a helix–turn–helix motif from RSV F and recognized by an RSV-neutralizing antibody was generated as a scaffold using computational design methods (Correia et al. 2014).”
MethodProcko, E., Berguig, G. Y., Shen, B. W., Song, Y., Frayo, S., Convertine, A. J., Margineantu, D., Booth, G., Correia, B. E., Cheng, Y., et al. (2014) · Cell · doi:10.1016/j.cell.2014.04.034 · Cited by 127
“of an Epstein-Barr Viral Bcl-2 Protein”
Self-citationDeep learning techniques have significantly impacted protein structure prediction and protein design
Pearce, R., & Zhang, Y. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.01.007 · Cited by 127
Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures
Eroshenko, N., Gill, T., Keaveney, M. K., Church, G. M., Trevejo, J., & Rajaniemi, H. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0577-1 · Cited by 126
Coiled coil protein origami: from modular design principles towards biotechnological applications
Lapenta, F., Aupič, J., Strmšek, Ž., & Jerala, R. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00822h · Cited by 123
Chen, F., Tzarum, N., Wilson, I. A., & Law, M. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.02.004 · Cited by 122
Jia, Y., Shen, G., Nguyen, S., Zhang, Y., Huang, K.-S., Ho, H.-Y., Hor, W.-S., Yang, C.-H., Bruning, J. B., Li, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.09.034942 · Cited by 119
Targeting protein–protein interactions, a wide open field for drug design
Bakail, M., & Ochsenbein, F. (2016) · Comptes Rendus. Chimie · doi:10.1016/j.crci.2015.12.004 · Cited by 117
RNA Virus Reverse Genetics and Vaccine Design
Stobart, C. C., & Moore, M. L. (2014) · Viruses · doi:10.3390/v6072531 · Cited by 131
“Current structural vaccinology efforts to evaluate the pre-fusion and post-fusion antigenic forms of RSV F protein have led to the induction and identification of potent neutralizing antibodies with higher neutralizing potencies than palivizumab [136,137].”
Geometric Principles for Designing Highly Symmetric Self-Assembling Protein Nanomaterials
Yeates, T. O. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-070816-033928 · Cited by 112
VanBlargan, L. A., Goo, L., & Pierson, T. C. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00024-15 · Cited by 118
“Finally, there is growing evidence that functionally relevant epitopes grafted onto molecular scaffolds can serve as promising immunogens (7, 297).”
BackgroundRapid search for tertiary fragments reveals protein sequence–structure relationships
Zhou, J., & Grigoryan, G. (2015) · Protein Science · doi:10.1002/pro.2610 · Cited by 105
De novo protein design by inversion of the AlphaFold structure prediction network
Goverde, C. A., Wolf, B., Khakzad, H., Rosset, S., & Correia, B. E. (2023) · Protein Science · doi:10.1002/pro.4653 · Cited by 103
Self-citationPredicting epitopes for vaccine development using bioinformatics tools
Yurina, V., & Adianingsih, O. R. (2022) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355221100218 · Cited by 115
“15 Bioinformatics or in silico studies, that is, computational methods that include mathematical, chemical, and biological approaches, are widely used in drug development.”
Wamhoff, E., Ronsard, L., Feldman, J. E., Knappe, G. A., Hauser, B. M., Romanov, A. M., Case, J. B., Sanapala, S., Lam, E. C., Denis, K. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44869-0 · Cited by 109
“Rational vaccine design often seeks to leverage multivalent antigen display together with epitope-focusing to generate potent, neutralizing antibody responses 76 .”
Bottom-up de novo design of functional proteins with complex structural features
Yang, C., Sesterhenn, F., Bonet, J., van Aalen, E. A., Scheller, L., Abriata, L. A., Cramer, J. T., Wen, X., Rosset, S., Georgeon, S., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00699-x · Cited by 84
Self-citationAdvanced subunit vaccine delivery technologies: From vaccine cascade obstacles to design strategies
Hou, Y., Chen, M., Bian, Y., Zheng, X., Tong, R., & Sun, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.006 · Cited by 104
Self-citationStructural and Computational Biology in the Design of Immunogenic Vaccine Antigens
Liljeroos, L., Malito, E., Ferlenghi, I., & Bottomley, M. J. (2015) · Journal of Immunology Research · doi:10.1155/2015/156241 · Cited by 115
“This information was used to design scaffolds presenting the epitope of which the best, MES1 (PDB ID: 3QWO), bound Motavizumab with high affinity but failed to induce protection in mice upon immunization [30] FFL 001 was the first example of a computationally designed scaffold that when used in immunization of macaque…”
MethodDNA Vaccines: Their Formulations, Engineering and Delivery
Kozak, M., & Hu, J. (2024) · Vaccines · doi:10.3390/vaccines12010071 · Cited by 115
“The idea of epitope-based vaccine engineering was first put forth in 2014 [82].”
BackgroundLee, J. H., de Val, N., Lyumkis, D., & Ward, A. C. (2015) · Structure · doi:10.1016/j.str.2015.07.020 · Cited by 92
“We have now shown that cryoEM is capable of generating rapid structural information for iterative, structure-based vaccine design (Correia et al., 2014; Jardine et al., 2013; McGuire et al., 2013; McLellan et al., 2013) as is being pursued for HIV-1.”
BackgroundProtective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever
Fels, J. M., Maurer, D. P., Herbert, A. S., Wirchnianski, A. S., Vergnolle, O., Cross, R. W., Abelson, D. M., Moyer, C. L., Mishra, A. K., Aguilan, J. T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.001 · Cited by 99
Immunostimulatory Polymers as Adjuvants, Immunotherapies, and Delivery Systems
Weiss, A. M., Hossainy, S., Rowan, S. J., Hubbell, J. A., & Esser-Kahn, A. P. (2022) · Macromolecules · doi:10.1021/acs.macromol.2c00854 · Cited by 94
Rapid Fine Conformational Epitope Mapping Using Comprehensive Mutagenesis and Deep Sequencing
Kowalsky, C. A., Faber, M. S., Nath, A., Dann, H. E., Kelly, V. W., Liu, L., Shanker, P., Wagner, E. K., Maynard, J. A., Chan, C., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.676635 · Cited by 82
The design of symmetric protein nanomaterials comes of age in theory and practice
Yeates, T. O., Liu, Y., & Laniado, J. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.07.003 · Cited by 89
Advanced technologies for the development of infectious disease vaccines
Gupta, A., Rudra, A., Reed, K., Langer, R., & Anderson, D. G. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01041-z · Cited by 100
Hajissa, K., Zakaria, R., Suppıan, R., & Mohamed, Z. (2019) · Journal of Advanced Veterinary and Animal Research · doi:10.5455/javar.2019.f329 · Cited by 85
“Accordingly, various immunogenic epitopes have been identified in different infectious pathogens and cancer, and they have significantly improved the development of potential epitope-based vaccines [50].”
BackgroundQi, Y., & Zhang, J. Z. H. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00043 · Cited by 78
Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity
Earnest, J. T., Basore, K., Roy, V., Bailey, A. L., Wang, D., Alter, G., Fremont, D. H., & Diamond, M. S. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190736 · Cited by 78
“Our results in mice suggest than immunization strategies that use protein scaffolds (Correia et al., 2014) and specific TH1skewing adjuvants could target regions in the B domain of E2, the FL of E1, and possibly other sites to generate neutralizing antibodies that block viral fusion and egress and optimize Fc effector…”
BackgroundGuarra, F., & Colombo, G. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00513 · Cited by 87
Computational tools for epitope vaccine design and evaluation
He, L., & Zhu, J. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.013 · Cited by 81
“In a breakthrough study, a computational procedure termed “fold from loops” was used to design an epitope scaffold that elicited RSV-neutralizing antibodies in rhesus macaques [30].”
MethodRecent advances on smart glycoconjugate vaccines in infections and cancer
Anderluh, M., Berti, F., Bzducha‐Wróbel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik-Popińska, K., Ferhati, X., Holmdahl, R., Jovanović, D. J., et al. (2021) · FEBS Journal · doi:10.1111/febs.15909 · Cited by 76
He, L., Cheng, Y., Kong, L., Azadnia, P., Giang, E., Kim, J. J., Wood, M. R., Wilson, I. A., Law, M., & Zhu, J. (2015) · Scientific Reports · doi:10.1038/srep12501 · Cited by 77
Melero, J. A., Mas, V., & McLellan, J. S. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.09.045 · Cited by 73
Variability in Humoral Immunity to Measles Vaccine: New Developments
Haralambieva, I. H., Kennedy, R. B., Ovsyannikova, I. G., Whitaker, J. A., & Poland, G. A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.10.005 · Cited by 78
Gainza, P., Nisonoff, H. M., & Donald, B. R. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.03.006 · Cited by 71
Scally, S. W., McLeod, B., Bosch, A., Miura, K., Liang, Q., Carroll, S., Reponen, S., Nguyen, T. K. N., Giladi, E., Rämisch, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01924-3 · Cited by 80
Self-citationProtein scaffolds: antibody alternatives for cancer diagnosis and therapy
Luo, R., Liu, H., & Cheng, Z. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00094f · Cited by 83
Sudha, G., Nussinov, R., & Srinivasan, N. (2014) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2014.07.004 · Cited by 73
Clinical Potential of Prefusion RSV F-specific Antibodies
Rossey, I., McLellan, J. S., Saelens, X., & Schepens, B. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.09.009 · Cited by 73
Adversomics: a new paradigm for vaccine safety and design
Whitaker, J. A., Ovsyannikova, I. G., & Poland, G. A. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1038249 · Cited by 76
“The studies of these adverse vaccine outcomes have informed the structure-based design of new RSV vaccine candidates [93,94].”
Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability
Mason, R. D., Welles, H. C., Adams, C., Chakrabarti, B. K., Gorman, J., Zhou, T., Nguyen, R., O'Dell, S. J., Lusvarghi, S., Bewley, C. A., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005537 · Cited by 69
“Design of a HIV immunogen that can i) focus the antibody response to protective yet subdominant or sterically hindered epitopes, ii) engage Abs encoded by germline B cell receptors (BCRs) and iii) drive sufficient antibody affinity maturation to generate protective antibody responses will likely require iterative immu…”
Self-citationProtein design via deep learning
Ding, W., Nakai, K., & Gong, H. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac102 · Cited by 66
“Examples could be found everywhere in our daily life, including designed small-molecule binding proteins that are used in in vivo biosensors [136, 137], designed biomedical inhibitors that aim to prevent viral infections [138], designed enzymes that have attractive catalytic efficiencies [139–141], designed highly sym…”
Murin, C. D., Julien, J., Sok, D., Stanfield, R. L., Khayat, R., Cupo, A., Moore, J. P., Burton, D. R., Wilson, I. A., & Ward, A. B. (2014) · Journal of Virology · doi:10.1128/jvi.01229-14 · Cited by 74
Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design
Crowe, J. E. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.07.013 · Cited by 67
“Computational design of an α-helical protein scaffold that presented the correct conformation of the minimal palivizumab epitope (a small helix-loop-helix structure) discovered a structure that induced neutralizing antibodies to the epitope that bound in a similar manner to that of palivizumab (Correia et al., 2014).”
BackgroundResultInfluentialSelf-citationMarchand, A., Van Hall-Beauvais, A. K., & Correia, B. E. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102370 · Cited by 65
Self-citation
Metadata
- Authors
- Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., Connell, M. J., Stevens, E., Schroeter, A., Chen, M., MacPherson, S., Serra, A. M., Adachi, Y., Holmes, M. A., Li, Y., Klevit, R. E., Graham, B. S., Wyatt, R. T., Baker, D., Strong, R. K., Crowe, J. E., Johnson, P. R., & Schief, W. R.
- Affiliations
- Scripps Research Institute (US)
- Vanderbilt University Medical Center (US)
- Children's Hospital of Philadelphia (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- National Institutes of Health (US)
- Corresponding author
- Schief, William R.
- ORCID
- Venue
- Nature
- Published
- 2014-02-05
- Volume
- 507
- Issue
- 7491
- Pages
- 201-206
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4260937
- OpenAlex
- W2040299410
- Cited by
- 555
- References
- 38
- Citations by year
- 2026: 39 · 2025: 40 · 2024: 37 · 2023: 32 · 2022: 55 · 2021: 44 · 2020: 43 · 2019: 45 · 2018: 40 · 2017: 47 · 2016: 50 · 2015: 52 · 2014: 30
- FWCI
- 24.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc)
- PubMed Central (acceptedVersion, cc-by-nc)
- Funders
- Bill and Melinda Gates Foundation
- International AIDS Vaccine Initiative
- March of Dimes Foundation
- Children's Hospital of Philadelphia
- University of Washington
- National Institutes of Health
- Center for AIDS Research, University of Washington
- University of California, San Diego
- National Cancer Institute (T32CA080416)
- National Institute of General Medical Sciences (T32GM007270)
- National Institute of Allergy and Infectious Diseases (P30AI 36214, U54AI057141, U54 AI 005714, R01AI102766, UM1AI100663, R21AI088554, P01AI094419, P30AI036214, P30AI045008)
- Center for AIDS Research, University of California, San Diego
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- RSV vaccine, neutralizing antibodies, computational protein design, protein scaffolds, antigenic determinants, vaccine development
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibodies, Viral, Epitopes, Antigens, Viral, Enzyme-Linked Immunosorbent Assay, Macaca mulatta, Male, Mice, Inbred BALB C, Models, Molecular, Neutralization Tests, Protein Conformation, Respiratory Syncytial Viruses, Drug Design, Crystallography, X-Ray, Amino Acid Motifs, Respiratory Syncytial Virus Vaccines, Mice, Protein Stability, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.